Stocks Screener

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Mustang Bio Inc

MBIO
Current price
0.25 USD -0.023 USD (-8.55%)
Last closed 0.24 USD
ISIN US62818Q1040
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 9 531 546 USD
Yield for 12 month -85.75 %
1Y
3Y
5Y
10Y
15Y
MBIO
21.11.2021 - 28.11.2021

Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-117 and MB-217, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-101 CAR T cell program for glioblastoma; MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, CSL Behring; Mayo Clinic; Leiden University Medical Centre; SIRION Biotech GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts. Avenue Mustang Bio, Inc. is a subsidiary of Fortress Biotech, Inc. Address: 377 Plantation Street, Worcester, MA, United States, 01605

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

10 USD

P/E ratio

Dividend Yield

Current Year

Last Year

Current Quarter

Last Quarter

Current Year

-2 225 000 USD

Last Year

-3 031 000 USD

Current Quarter

-300 000 USD

Last Quarter

-696 000 USD

Key Figures MBIO

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -30 498 000 USD
Operating Margin TTM
PE Ratio
Return On Assets TTM -105.16 %
PEG Ratio
Return On Equity TTM -1191.31 %
Wall Street Target Price 10 USD
Revenue TTM -50 000 USD
Book Value -0.24 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY
Dividend Yield
Gross Profit TTM
Earnings per share -2.72 USD
Diluted Eps TTM -2.72 USD
Most Recent Quarter II 2024
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics MBIO

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History MBIO

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor 1:15
Payout Ratio
Last Split Date 04.04.2023
Dividend Date

Stock Valuation MBIO

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue
Price Sales TTM
Enterprise Value EBITDA -0.1428
Price Book MRQ 31.7451

Financials MBIO

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators MBIO

For 52 weeks

0.13 USD 1.97 USD
50 Day MA 0.26 USD
Shares Short Prior Month 382 144
200 Day MA 0.56 USD
Short Ratio 1.16
Shares Short 501 966
Short Percent 1.39 %